Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer

View More View Less
  • a From the Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island; Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, West Virginia; Sunovion Pharmaceuticals, Marlborough, Massachusetts; Department of Biostatistics, School of Public Health, West Virginia University, Morgantown, West Virginia; and Department of Surgery, School of Medicine, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia.
Restricted access

Background: Understanding the patterns of healthcare utilization and costs during the initial phase of care (12 months after breast cancer [BC] diagnosis) in older women (aged ≥65 years) is crucial in the allocation of Medicare resources. The objective of this study was to determine healthcare utilization and costs during the initial phase of care in older, female, Medicare fee-for-service beneficiaries diagnosed with BC, and to determine the factors associated with higher costs. Methods: A retrospective observational study using the SEER-Medicare linked database was conducted in 69,307 women aged ≥66 years diagnosed with primary incident BC in 2003–2009 to determine healthcare utilization, average costs, and costs for specific services during the initial phase of care. Generalized linear model regression was conducted to identify the factors associated with higher costs in a multivariate framework. Results: A total of 96% of women were treated with surgery during the initial phase of BC care, whereas 21% and 54% underwent chemotherapy and radiotherapy, respectively. Costs during the initial phase of care totalled $28,075 in 2012 USD, comprising $13,344 for physician services and $7,456 for outpatient services. Factors associated with higher costs during the initial phase of care were younger age (66–69 years), African American race, higher household income, advanced stages of BC, initial BC treatment, higher number of primary care physician visits, and presence of comorbidities and/or a mental condition. Conclusions: The economic burden of BC is substantial during the initial phase of care. Physician and outpatient services accounted for the highest proportion of costs. Predisposing factors, need-related factors, healthcare use, and external environmental healthcare factors significantly predicted costs during the initial phase of care.

Author contributions: Study concept and design: Vyas, Madhavan, Sambamoorthi, Pan, Regier, Hazard. Data acquisition: Vyas, Madhavan, Sambamoorthi, Kalidindi. Data analysis: Vyas, Madhavan, Sambamoorthi, Kalidindi. Data interpretation: All authors. Manuscript preparation: All authors. Final approval: All authors.

Correspondence: Ami Vyas, PhD, University of Rhode Island, College of Pharmacy, Department of Pharmacy Practice, 7 Greenhouse Road, Kingston, RI 02881. E-mail: avyas@uri.edu
  • 1.

    Mariotto AB, Yabroff KR, Shao Y. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117128.

    • Search Google Scholar
    • Export Citation
  • 2.

    Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40(8 Suppl):IV-104117.

    • Search Google Scholar
    • Export Citation
  • 3.

    Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 2009;27:199209.

    • Search Google Scholar
    • Export Citation
  • 4.

    Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828841.

    • Search Google Scholar
    • Export Citation
  • 5.

    Warren JL, Brown ML, Fay MP. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol 2002;20:307316.

    • Search Google Scholar
    • Export Citation
  • 6.

    Yabroff KR, Lamont EB, Mariotto AB. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630641.

  • 7.

    Howlader N, Noone AM, Krapcho M, eds. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, based on November 2011 SEER data submission, April 2012. Available at: http://seer.cancer.gov/csr/1975_2013/. Accessed January 21, 2017.

    • Search Google Scholar
    • Export Citation
  • 8.

    Yabroff KR, Warren JL, Brown M. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 2007;4:643656.

  • 9.

    Hanchate AD, Clough-Gorr KM, Ash AS. Longitudinal patterns in survival, comorbidity, healthcare utilization and quality of care among older women following breast cancer diagnosis. J Gen Intern Med 2010;25:10451050.

    • Search Google Scholar
    • Export Citation
  • 10.

    Warren JL, Yabroff KR, Meekins A. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100:888897.

  • 11.

    Penberthy L, Retchin SM, McDonald MK. Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer. Health Care Manag Sci 1999;2:149160.

    • Search Google Scholar
    • Export Citation
  • 12.

    Warren JL, Klabunde CN, Schrag D. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl):IV-318.

    • Search Google Scholar
    • Export Citation
  • 13.

    Engels EA, Pfeiffer RM, Ricker W. Use of Surveillance, Epidemiology, and End Results-Medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol 2011;174:860870.

    • Search Google Scholar
    • Export Citation
  • 14.

    National Cancer Institute, Division of Cancer Control & Population Sciences. SEER-Medicare: About the Data Files. Available at: http://healthcaredelivery.cancer.gov/seermedicare/aboutdata/. Accessed January 21, 2017.

    • Search Google Scholar
    • Export Citation
  • 15.

    U.S. Health Resources and Services Administration. Bureau of Health Professions. Area Resource File, 2009–2010 Release. Rockville, MD: US Department of Health and Human Services; Fairfax, VA: Quality Resource Systems, Inc; 2010. Codebook: HE-001(2010).

    • Search Google Scholar
    • Export Citation
  • 16.

    Taplin SH, Barlow W, Urban N. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417426.

    • Search Google Scholar
    • Export Citation
  • 17.

    Finkler SA. The distinction between cost and charges. Ann Intern Med 1982;96:102109.

  • 18.

    United States Department of Labor Bureau of Labor Statistics. Consumer price index, medical care services, 1982-84. Available at: https://www.bls.gov/cpi/. Accessed January 21, 2017.

    • Search Google Scholar
    • Export Citation
  • 19.

    Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973;51:95124.

    • Search Google Scholar
    • Export Citation
  • 20.

    Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;36:110.

  • 21.

    Young JL Jr, Roffers SD, Ries LA, eds. SEER Summary Staging Manual – 2000: Codes and Coding Instructions, NIH Pub. No. 01-4969. Bethesda, MD: National Cancer Institute; 2001.

    • Search Google Scholar
    • Export Citation
  • 22.

    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:12581267.

    • Search Google Scholar
    • Export Citation
  • 23.

    National Cancer Institute, Division of Cancer Control & Population Sciences. SEER-Medicare: Calculation of Comorbidity Weights. Available at: https://healthcaredelivery.cancer.gov/seermedicare/considerations/calculation.html. Accessed January 21, 2017.

    • Search Google Scholar
    • Export Citation
  • 24.

    Yu X, McBean AM, Virnig BA. Physician visits, patient comorbidities, and mammography use among elderly colorectal cancer survivors. J Cancer Surviv 2007;1:275282.

    • Search Google Scholar
    • Export Citation
  • 25.

    Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283295.

  • 26.

    Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461494.

  • 27.

    FDA Approved Drugs for Oncology: Drugs Approved in 2017. Available at: https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology. Accessed April 28, 2017.

    • Search Google Scholar
    • Export Citation
  • 28.

    Howard DH, Chernew ME, Abdelgawad T. New anticancer drugs associated with large increases in costs and life expectancy. Health Affairs 2016;35:15811587.

    • Search Google Scholar
    • Export Citation
  • 29.

    Roberts KB, Soulos PR, Herrin J. The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications. Int J Radiat Oncol Biol Phy 2013;85:11861192.

    • Search Google Scholar
    • Export Citation
  • 30.

    Tuttle TM, Rueth NM, Abbott A, Virnig BA. Trends in the local treatment of breast cancer: should we be worried? J Surg Oncol 2011;103:313316.

  • 31.

    Yang RL, Newman AS, Lin IC. Trends in immediate breast reconstruction across insurance groups after enactment of breast cancer legislation. Cancer 2013;119:24622468.

    • Search Google Scholar
    • Export Citation
  • 32.

    Kennedy T, Stewart AK, Bilimoria KY. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients. Ann Surg Oncol 2007;14:29182927.

    • Search Google Scholar
    • Export Citation
  • 33.

    Shih YC, Elting LS, Halpern MT. Factors associated with immunotherapy use among newly diagnosed cancer patients. Med Care 2009;47:948958.

  • 34.

    Halpern MT, Yabroff KR. Prevalence of outpatient cancer treatment in the United States: estimates from the Medical Expenditures Panel Survey (MEPS). Cancer Invest 2008;26:647651.

    • Search Google Scholar
    • Export Citation
  • 35.

    Rubenstein EB. Costs and benefits of outpatient therapy. Support Care Cancer 1994;2:307311.

  • 36.

    Busch E, Kemeny M, Fremgen A. Patterns of breast cancer care in the elderly. Cancer 1996;78:101111.

  • 37.

    Silliman RA, Troyan SL, Guadagnoli E. The impact of age, marital status, and physician-patient interactions on the care of older women with breast carcinoma. Cancer 1997;80:13261334.

    • Search Google Scholar
    • Export Citation
  • 38.

    Escarce JJ, Epstein KR, Colby DC. Racial differences in the elderly's use of medical procedures and diagnostic tests. Am J Public Health 1993;83:948954.

    • Search Google Scholar
    • Export Citation
  • 39.

    Gornick ME, Eggers PW, Reilly TW. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med 1996;335:791799.

    • Search Google Scholar
    • Export Citation
  • 40.

    Subramanian S, Tangka FK, Sabatino SA. Impact of chronic conditions on the cost of cancer care for Medicaid beneficiaries. Medicare Medicaid Res Rev 2013;2:pii: mmrr.002.04.a07.

    • Search Google Scholar
    • Export Citation
  • 41.

    Wodchis WP, Arthurs E, Khan AI. Cost trajectories for cancer patients. Curr Oncol 2016;23(Suppl 1):S6475.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 237 161 3
PDF Downloads 96 66 2
EPUB Downloads 0 0 0